ORIGINAL RESEARCH article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1633219
A rapid antigen test to detect adenosine deaminase 2 (ADA2) in biological fluids and its application in clinical diagnostics
Provisionally accepted
- 1Hainan Medical University, Haikou, China
- 2Zhejiang University, Hangzhou, China
- 3Hospital Universitari Arnau de Vilanova, Lleida, Spain
- 4Tulane National Primate Research Center, Covington, United States
- 5Turku Centre for Biotechnology, University of Turku, Turku, Finland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Saliva biomarkers provide a convenient and noninvasive method for diagnosing immune and genetic disorders. One such biomarker is adenosine deaminase 2 (ADA2), an enzyme that converts adenosine into inosine and is elevated in cancer and immune diseases. Currently, ADA2 activity can be used to diagnose pleural tuberculosis. Recently, we developed an ELISA assay that detects ADA2 in saliva. This test has been successfully employed to diagnose adenosine deaminase 2 deficiency (DADA2) and potentially to identify individuals with head and neck cancer. DADA2 is a rare genetic disease that can lead to systemic vasculitis, early-onset stroke, bone marrow failure, and/or immunodeficiency. A rapid, simple, and affordable point-of-care (POC) test would significantly aid in diagnosing DADA2 and facilitate appropriate treatment. In this study, we created a novel colloidal gold-based immunochromatographic strip (ICS) containing polyclonal antigen-purified anti-ADA2 antibodies. The ADA2 rapid antigen test (RAT) was calibrated precisely to detect ADA2 in the saliva of healthy individuals, while those with ADA2 deficiency received negative results. The test successfully confirmed DADA2 in nine patients with different pathogenic mutations in ADA2, while 58 of 59 healthy donors tested positive for ADA2. The ADA2 rapid antigen test reliably screens patients with autoimmune disorders, accurately diagnosing DADA2. This test can also be used to diagnose pleural tuberculosis or other diseases with significantly elevated ADA2 levels.
Keywords: Adenosine deaminase 2, ADA2 deficiency, dada2, Pleural tuberculosis, Rapid antigen test
Received: 22 May 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 Yang, Zhou, Porcel, Wang, Wu and Zavialov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Andrey Zavialov, Turku Centre for Biotechnology, University of Turku, Turku, Finland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.